Navigation Links
Knocking Out Survival Protein Could Aid Leukemia Treatment

An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study// shows.

The findings suggest that a drug that can block this 'survival protein' might on its own be an effective therapy.

But such a drug used in combination with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly.

The survival protein is called Mcl1. It usually helps keep normal cells healthy and is involved in the development of the components of the immune system, but it can also help prolong survival of cancer cells.

Cells with an overabundance of the protein are also more resistant to anticancer drugs such as rituximab, which has revolutionized the treatment of certain chronic and acute leukemias.

The study by researchers at the Ohio State University Comprehensive Cancer Center is published online in the journal Clinical Cancer Research.

'Our findings demonstrate that Mcl1 may be an effective target for drugs directed against CLL and ALL,' says principal investigator John C. Byrd, professor of internal medicine and director of the hematologic malignancies program at Ohio State's James Cancer Hospital and Solove Research Institute.

'These results give us a rationale for lowering the amount of this protein in CLL cells and suggest that this should enhance the action of rituximab and perhaps other agents as well.'

Rituximab is an antibody-based drug that targets CLL and ALL cells and causes the cells to self-destruct.

'We've shown that knocking down Mcl1 can, by itself, cause CLL cells to die, and that this effect might enhance the activity of rituximab,' says first author Rehan Hussain, a postdoctoral fellow with Ohio State's Comprehensive Cancer Center.

Byrd, Hussain and their collaborators conducted this research using cancer cells from 17 CLL patients and ALL cell lines grown in the laboratory.

The investigators placed molecules called small interfering RNA (siRNA) inside the cells and found that the tiny molecules greatly reduced the amount of the survival protein, causing many of the cells to die. The effect was the same even in cells that came from patients with advanced cancer or from patients with tumors that resisted conventional treatment.

When the researchers treated cells with both siRNA and the drug rituximab, the combination killed significantly more leukemia cells than the drug alone.

Overall, says Byrd, 'Our data indicate that specifically targeting Mcl1 might be effective in the treatment of CLL, particularly when combined with rituximab.'

Funding from the National Cancer Institute, the Leukemia & Lymphoma Society and the D. Warren Brown Foundation supported this research. Byrd is the D. Warren Brown Professor of Leukemia Research and a Clinical Scholar of the Leukemia & Lymphoma Society.

Source-Generef.com/B
'"/>




Related medicine news :

1. Knocking Out Survival Protein Could Fight Leukemia
2. Long-Term Survival can be Predicted by a Simple Lung Test
3. Hepatitis G May Boost HIV Survival
4. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
5. Longer Lung Cancer Survival
6. ICU Survival can be improved by Antibiotic use
7. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
8. Improving Survival Rate Of Lung Cancer Patients
9. Combination Therapy Effective In Improving Lung Cancer Survival
10. Symptoms Found To Be A Good Predictor Of Cancer Survival
11. Survival Of Colon Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... From the ... Presence Technology will share its insights on managing Customers Engagement at SpeechTek ... At SpeechTek 2016, Presence Technology will deliver a Presentation on “5 Customer ...
(Date:5/6/2016)... Diego, CA (PRWEB) , ... May 06, 2016 , ... ... Companies, has been family-owned and operated for over 35 years. Maintaining core values of ... has driven their success and made them a leading name in San Diego plumbing, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... This Mother’s Day ... women everywhere. The 17th annual National Women’s Health Week takes place May ... Women’s Health are combining forces to empower women to make their health a top ...
(Date:5/5/2016)... ... May 05, 2016 , ... TransWipe Volume 3 is a ... Drag and drop a TransWipe preset between two video clips to instantly add a ... to colored panels with customizable color and orientation options. TransWipe Volume 3 is a ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
Breaking Medicine Technology: